诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

休市中 12-06 16:00:00 EST

110.77

+1.95

+1.79%

盘后110.74

-0.03-0.03%

19:59 EST

最高111.31	最低109.75	成交量604.56万
今开109.93	昨收108.82	日振幅1.43%
总市值4,901亿	流通市值3,505亿	总股本44.24亿
成交额6.70亿	换手率0.19%	流通股本31.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":110.77,"timestamp":1733518800000,"preClose":108.82,"halted":0,"volume":6045582,"hourTrading":{"tag":"盘后","latestPrice":110.74,"preClose":110.77,"latestTime":"19:59 EST","volume":18778,"amount":2078872.4921,"timestamp":1733533165369},"delay":0,"floatShares":3164393375,"shares":4424320356,"eps":3.170878,"marketStatus":"休市中","marketStatusCode":7,"change":1.95,"latestTime":"12-06 16:00:00 EST","open":109.93,"high":111.3061,"low":109.75,"amount":670293143.11404,"amplitude":0.0143,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.170878,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1733734800000},"adr":1,"listingDate":363499200000,"adjPreClose":108.82,"adrRate":1,"dividendRate":0.013154,"preHourTrading":{"tag":"盘前","latestPrice":109.97,"preClose":108.82,"latestTime":"09:29 EST","volume":25730,"amount":2833022.7486,"timestamp":1733495370065},"postHourTrading":{"tag":"盘后","latestPrice":110.74,"preClose":110.77,"latestTime":"19:59 EST","volume":18778,"amount":2078872.4921,"timestamp":1733533165369},"volumeRatio":1.442730542644169,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1734670800000,"strike":"105.0","timestamp":1733510927821,"price":3,"volume":2915,"amount":874500,"type":"+"},{"symbol":"NVO","call":true,"expireDate":1734066000000,"strike":"125.0","timestamp":1733496856590,"price":0.6700000166893005,"volume":1550,"amount":103850,"type":"+"}]},"impliedVol":0.5221,"impliedVolPercentile":0.9563},"requestUrl":"/m/hq/s/NVO/wiki","defaultTab":"wiki","newsList":[{"id":"2489503213","title":"欧盟无条件批准诺和控股收购药品代工商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2489503213","media":"界面","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489503213?lang=zh_cn&edition=full","pubTime":"2024-12-07 11:58","pubTimestamp":1733543912,"startTime":"0","endTime":"0","summary":"欧盟委员会12月6日宣布，无条件批准诺和诺德大股东诺和控股（Novo Holdings）收购生物制药合同制造商康泰伦特的交易，定该交易不会在欧洲经济区引发竞争问题。诺和控股今年2月宣布，将以全现金交易形式收购康泰伦特，加上债务的企业总价值达到165亿美元。作为交易的一部分，诺和诺德将以110亿美元的预付款从诺和控股手中收购康泰伦特位于意大利阿纳尼、比利时布鲁塞尔和美国印第安纳州布卢明顿的三座灌装工厂，旨在提升产能。根据声明，这三座工厂拥有超3000名员工，均与诺和诺德保持着合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120711583398e600fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120711583398e600fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4585","IE00BZ1G4Q59.USD","NVO","IE00BKVL7J92.USD","BK4532","BK4599","LU1093756325.SGD","BK4588","BK4007","LU1093756168.USD"],"gpt_icon":0},{"id":"2489459267","title":"诺和诺德将把两种胰岛素产品的美国上市价格下调 70% 以上","url":"https://stock-news.laohu8.com/highlight/detail?id=2489459267","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489459267?lang=zh_cn&edition=full","pubTime":"2024-12-05 21:37","pubTimestamp":1733405829,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社哥本哈根12月5日 - 丹麦制药商诺和诺德  周四表示，公司计划从2026年1月起将两种胰岛素产品的美国上市价格降低70%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0154236417.USD","BK4585","BK4599","BK4532","BK4007","NVO","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2489414937","title":"司美格鲁肽疗效被大幅超越，减重药竞争进入“深水区”，价格战还远吗","url":"https://stock-news.laohu8.com/highlight/detail?id=2489414937","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489414937?lang=zh_cn&edition=full","pubTime":"2024-12-05 18:52","pubTimestamp":1733395931,"startTime":"0","endTime":"0","summary":"12月4日夜间，礼来放出“重磅炸弹”，称在一项头对头的三期临床研究中，其GIP/GLP-1双受体激动剂替尔泊肽的减重效果大幅超越诺和诺德的司美格鲁肽。这一消息推动礼来当天股价收盘大涨超过2%，市值逼近7900亿美元。    GLP-1药物在过去一年里成为多家巨头药企争相布局的热门赛道。巴克莱银行预计，到2030年，全球减重药物市...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OWn_ChtjTvfOuLCip5xxdGf73NOLPhIeg684nn2gbWy3IAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OWn_ChtjTvfOuLCip5xxdGf73NOLPhIeg684nn2gbWy3IAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241205A089JG00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241205A089JG00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4585","LU1093756168.USD","BK4532","BK4007","LU1093756325.SGD","NVO","IE00BKVL7J92.USD","BK4599","LU0154236417.USD","BK4588","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2489248313","title":"“减肥双雄”首次“头对头”PK：礼来赢了诺和诺德，高盛：市场早就知道了","url":"https://stock-news.laohu8.com/highlight/detail?id=2489248313","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489248313?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:03","pubTimestamp":1733382221,"startTime":"0","endTime":"0","summary":"高盛表示，这一结果符合市场普遍预期，即Zepbound的减肥效果显著优于诺和诺德。并认为诺和诺德与礼来将控制80%的减肥药市场，二者间的比例为40%和60%。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/7678664b-3b5f-4fc3-ab6c-6b8931f66efb.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/7678664b-3b5f-4fc3-ab6c-6b8931f66efb.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3736139","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3736139","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK4504","SG9999018865.SGD","LU2360106947.USD","IE00B2B36J28.USD","LU1804176565.USD","LU0109391861.USD","LU1868837300.USD","IE00BSNM7G36.USD","LLY","LU0061475181.USD","LU0820561818.USD","LU2468319806.SGD","LU0456855351.SGD","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4516","IE0009355771.USD","SG9999014914.USD","LU1035775433.USD","LU2237443549.SGD","IE00BK4W5M84.HKD","LU0203202063.USD","LU2089984988.USD","LU0198837287.USD","BK4127","SG9999015952.SGD","IE00BK4W5L77.USD","LU2237443978.SGD","PK","IE00B19Z3B42.SGD","LU2112291526.USD","LU2237438978.USD","IE0002270589.USD","SGXZ51526630.SGD","LU2237443895.HKD","IE00B1BXHZ80.USD","LU1267930730.SGD","LU1093756325.SGD","LU1974910355.USD","BK4532","NVO","LU0640476718.USD","SG9999015978.USD","SG9999014898.SGD","LU0708995401.HKD","LU1127390331.HKD","LU2237443465.HKD","LU0238689110.USD","LU0823416689.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2489717197","title":"礼来(LLY)：Zepbound在减重效果上胜过诺和诺德(NVO)的Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2489717197","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489717197?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:51","pubTimestamp":1733363486,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美国大型制药企业礼来(LLY)宣布，在一项对比研究中，其研发的减肥药Zepbound在减重效果上超越了诺和诺德(NVO)的Wegovy。研究数据显示，服用Zepbound的参与者体重平均下降了20.2%，相比之下，使用Wegovy的参与者体重减轻了13.7%。礼来公司打算将这些研究成果提交至同行评审的学术期刊，并计划在即将举行的医学会议上公布这些数据。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210625/NzU1OThlNmM0MjcyNDY3NGZjMzI1Mzg0Mzg5MzM5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NzU1OThlNmM0MjcyNDY3NGZjMzI1Mzg0Mzg5MzM5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00BDT5M118.USD","LU0708995401.HKD","LU0471298777.SGD","IE00BJLML261.HKD","LU0061475181.USD","LU2237443622.USD","LU2237443978.SGD","LU2237443549.SGD","SG9999014898.SGD","LU2264538146.SGD","LU1868836914.USD","LU0456855351.SGD","LU1868837300.USD","BK4588","IE00BKVL7J92.USD","NVO","LU0058720904.USD","LU1127390331.HKD","IE00BZ1G4Q59.USD","SG9999015978.USD","LU2211815571.USD","LU1623119135.USD","LU0354030438.USD","LU1061106388.HKD","LLY","IE00BK4W5L77.USD","LU2265009873.SGD","LU2023250504.SGD","LU0466842654.USD","LU1551013342.USD","BK4532","LU2461242641.AUD","SG9999001176.USD","SG9999018857.SGD","LU1064131342.USD","LU1069344957.HKD","LU0203201768.USD","LU2237443465.HKD","LU2602419157.SGD","LU2361044865.SGD","IE0004445239.USD","LU2089984988.USD","IE0009355771.USD","LU2324357040.USD","LU2106854487.HKD","LU0114720955.EUR","LU1917777945.USD","SG9999015945.SGD","LU2237443382.USD","SG9999018865.SGD"],"gpt_icon":0},{"id":"2488980391","title":"诺瓦瓦克斯医药以2亿美元出售于捷克的生产设施给诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=2488980391","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488980391?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:05","pubTimestamp":1733360732,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺瓦瓦克斯医药(NVAX)将其位于捷克的生产设施以2亿美元出售给诺和诺德(NVO)。根据周三公布的声明，诺瓦瓦克斯医药将向诺和诺德装让一个15万平方英尺的重组蛋白制造设施及配套建筑，现有的劳动力以及所有相关和必要的基础设施。除了2024年1.9亿美元的现金支付和2025年额外的1000万美元外，诺瓦瓦克斯医药预计出售该设施将使每年的运营成本降低约8000万美元。该协议预计将于2024年12月30日完成，届时该生产设施的全部责任将转交给诺和诺德。","market":"us","thumbnail":"https://static.tigerbbs.com/015e8bdc1b4c937bb6bf446ba9f471f1","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/015e8bdc1b4c937bb6bf446ba9f471f1"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"282753","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺瓦瓦克斯医药以2亿美元出售于捷克的生产设施给诺和诺德","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","NVO","BK4532","BK4007","LU1093756168.USD","BK4139","BK4568","LU0154236417.USD","BK4599","BK4585","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4547"],"gpt_icon":0},{"id":"2489711104","title":"礼来公布对比试验结果：Zepbound减肥效果好于诺和诺德Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2489711104","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489711104?lang=zh_cn&edition=full","pubTime":"2024-12-05 01:00","pubTimestamp":1733331600,"startTime":"0","endTime":"0","summary":"　　美国制药巨头礼来公司周三宣布，在一次对比试验中，其减肥药物Zepbound的减重效果高于竞争对手诺和诺德的同类药物Wegovy。　　这项对比试验由礼来赞助，其结果显示，使用Zepbound的患者在经过72周的治疗后体重平均减轻了20.2%，而使用Wegovy的患者体重减轻了13.7%。　　礼来公司表示，在对比试验中，Zepbound的相对减重效果比Wegovy高出47%。　　对礼来而言，Zepbound的减重效果上更突出或许能帮助其在减肥药市场领先于诺和诺德。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e266721f8746851af3f56ae2b1743ae8","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-12-05/doc-incyirkf3557420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1868836757.USD","LU0122379950.USD","LLY","LU1064131342.USD","SG9999015978.USD","LU1917777945.USD","LU1551013342.USD","IE0004445239.USD","LU0943347566.SGD","LU1267930730.SGD","LU0820561818.USD","LU0114720955.EUR","IE00B4R5TH58.HKD","LU2063271972.USD","SG9999014898.SGD","IE00BFTCPJ56.SGD","LU1804176565.USD","LU2265009873.SGD","SG9999017495.SGD","IE00BKVL7J92.USD","LU2237443382.USD","LU0079474960.USD","LU0640476718.USD","LU2461242641.AUD","LU0198837287.USD","LU1061106388.HKD","LU0471298694.HKD","NVO","BK4532","LU2491050071.SGD","LU1712237335.SGD","LU0689472784.USD","LU0708995401.HKD","SGXZ99366536.SGD","LU1989771016.USD","LU0320765059.SGD","BK4588","LU1291159041.SGD","SG9999015945.SGD","BK4599","LU0097036916.USD","LU1035775433.USD","LU0820561909.HKD","SG9999013999.USD","SG9999015986.USD","LU2112291526.USD","LU0109391861.USD","LU2237443978.SGD","LU0061475181.USD","LU2468319806.SGD"],"gpt_icon":1},{"id":"1125652118","title":"美股异动 | 礼来涨超2%，减肥药对比实验力压诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=1125652118","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125652118?lang=zh_cn&edition=full","pubTime":"2024-12-04 22:50","pubTimestamp":1733323824,"startTime":"0","endTime":"0","summary":"本周三（12月4日），礼来减肥药Zepbound在首次对比试验中超越诺和诺德的Wegovy，美股盘前涨超2%，截至发稿报833.96美元：","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e266721f8746851af3f56ae2b1743ae8","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"礼来涨超2%，减肥药对比实验力压诺和诺德","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","LLY"],"gpt_icon":0},{"id":"2488194256","title":"“小非农”略低于预期 美国三大股指小幅高开","url":"https://stock-news.laohu8.com/highlight/detail?id=2488194256","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488194256?lang=zh_cn&edition=full","pubTime":"2024-12-04 22:31","pubTimestamp":1733322689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NQmain","SGCmain","IVV","SDS","ESmain","MSCI","LU0109391861.USD","SDOW","LLY","SPXU","GCmain","DUST","GDX","MNQmain",".DJI","LU2265009873.SGD","QQQ","NUGT","FDN","SPY","UDOW","QID","DJX","DOG","EEMA","DDM","TQQQ","159659",".SPX","159934","YMmain","OEF","03086","SQQQ","UPRO","NVO","SSO","SH",".IXIC","OEX","GLD","SGUmain","IAU","518880","DXD","PSQ","SImain","QLD","SG9999001176.SGD","MGCmain"],"gpt_icon":0},{"id":"2488519941","title":"礼来(LLY)盘前涨超1% 旗下减肥药Zepbound在对比试验中优于诺和诺德(NVO)的Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488519941","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488519941?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:54","pubTimestamp":1733320470,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)盘前涨超1%，截至发稿，报826.83美元。消息面上，礼来表示，其减肥药Zepbound在首次头对头试验(head-to-head trial)中表现优于竞争对手诺和诺德(NVO)的Wegovy。在礼来赞助的一项研究中，接受Zepbound治疗的人在72周内平均减掉了体重的20%，约50磅，而接受Wegovy治疗的人只减掉了14%。该结果证实了之前试验所显示的表明Zepbound具有更强效果的结论。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282761","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","LU0354030438.USD","LU0320765059.SGD","LU1868836914.USD","LU2237443622.USD","LU0354030511.USD","SG9999014898.SGD","LU2237438978.USD","LU2361044949.HKD","IE00BJT1NW94.SGD","NVO","LU1868837300.USD","LU2468319806.SGD","LU2361045086.USD","IE00BJLML261.HKD","LU1868837136.USD","LU0417517546.SGD","LU2237443465.HKD","SG9999014880.SGD","SG9999014906.USD","BK4532","LU1868836591.USD","GB00BDT5M118.USD","BK4534","LU0466842654.USD","SG9999014914.USD","SGXZ57979304.SGD","LU1057294990.SGD","LU2324357040.USD","LU1035775433.USD","SG9999017495.SGD","LU0820561818.USD","LU1267930730.SGD","LU1291159041.SGD","SG9999015952.SGD","LU2360106947.USD","LU2023250504.SGD","LLY","LU2491050071.SGD","LU2089984988.USD","LU1712237335.SGD","BK4581","IE0002141913.USD","LU1127390331.HKD","LU1974910355.USD","LU0689472784.USD","SGXZ81514606.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","LU0096364046.USD"],"gpt_icon":0},{"id":"2488196849","title":"金十数据整理：每日美股市场要闻速递（12月4日 周三）","url":"https://stock-news.laohu8.com/highlight/detail?id=2488196849","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488196849?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:35","pubTimestamp":1733319335,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NXPI","SGCmain","LLY","IE00B775SV38.USD","ES3.SI","GOOG","159582","161631","LU2106854487.HKD","DUST","STI.SI","LU2764263039.SGD","S68.SI","LU2041044095.USD","LU2065171402.SGD","MGCmain","LU1934455863.HKD","FSTM.SI","AAPL","MSFT","LU0795875169.SGD","LU0289961442.SGD","SG9999013999.USD","STLA","LU1917777945.USD","FTC","LU0061474705.USD","GDX","ADC","MRK","RIO.UK","LU1582987597.SGD","GCmain","159934","SImain","518880","GILD","IE00BN8TJ469.HKD","GOOGL","RIO","SG9999014914.USD","NUGT","NVO","CRM","FSTAS.SI","GLD","LU1280957306.USD","SGUmain","IAU"],"gpt_icon":0},{"id":"2488195857","title":"礼来(LLY)减肥药Zepbound在对比试验中优于诺和诺德(NVO)的Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488195857","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488195857?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:05","pubTimestamp":1733317515,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)表示，其减肥药Zepbound在首次头对头试验(head-to-head trial)中表现优于竞争对手诺和诺德(NVO)的Wegovy。在礼来赞助的一项研究中，接受Zepbound治疗的人在72周内平均减掉了体重的20%，约50磅，而接受Wegovy治疗的人只减掉了14%。该结果证实了之前试验所显示的表明Zepbound具有更强效果的结论。两种药物的副作用主要与胃肠道有关，并且较为相似。礼来公司表示，完整的研究结果将发表在同行评议的期刊上，并在明年的医学会议上发表。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282755","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","BK4534","LU1868837300.USD","LU0689472784.USD","LU0203201768.USD","LU1988902786.USD","LU2324357040.USD","LU0106261372.USD","SG9999015945.SGD","SG9999015986.USD","LU2237443549.SGD","LU0471298694.HKD","LU0820561818.USD","SG9999014914.USD","LU2265009873.SGD","LU1868836914.USD","SG9999015952.SGD","LU2112291526.USD","LU2491050154.USD","LU1868836591.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0320765059.SGD","LU0456855351.SGD","LU0640476718.USD","LU0079474960.USD","NVO","LU2237443382.USD","IE00BKVL7J92.USD","LU1127390331.HKD","LU1064131342.USD","LU1804176565.USD","SG9999018865.SGD","LU2361044949.HKD","SG9999001176.SGD","LU0256863811.USD","IE00BJJMRZ35.SGD","SGXZ51526630.SGD","LU2237438978.USD","LU0471298777.SGD","BK4007","LU1551013342.USD","LU0708995401.HKD","LU2461242641.AUD","LU1868836757.USD","LU0820561909.HKD","LU0417517546.SGD","LU0943347566.SGD","LU0061475181.USD"],"gpt_icon":0},{"id":"2488316087","title":"“减肥神药”对决：礼来的Zepbound力压诺和诺德的Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488316087","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488316087?lang=zh_cn&edition=full","pubTime":"2024-12-04 20:33","pubTimestamp":1733315584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e266721f8746851af3f56ae2b1743ae8","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0061475181.USD","LLY","BK4599","LU1023059063.AUD","LU0238689110.USD","LU0198837287.USD","NVO","LU1069344957.HKD","LU2264538146.SGD","LU1035775433.USD","BK4588","LU0097036916.USD","SG9999014898.SGD","IE00BFTCPJ56.SGD","LU0471298694.HKD","LU0203201768.USD","BK4585","LU2023250504.SGD","LU2360106947.USD","LU1551013342.USD","LU0943347566.SGD","LU1623119135.USD","LU1366192091.USD","LU0820561909.HKD","LU1267930730.SGD","LU2324357040.USD","SG9999014906.USD","BK4532","LU1804176565.USD","BK4581","LU0289739699.SGD","SG9999015978.USD","IE00BK4W5L77.USD","LU1127390331.HKD","LU2063271972.USD","LU1280957306.USD","SG9999015952.SGD","LU1814569148.SGD","LU2237443465.HKD","IE0009355771.USD","LU0385154629.USD","LU0466842654.USD","LU2237443978.SGD","SG9999001176.SGD","IE00B1BXHZ80.USD","SG9999015986.USD","LU0672654240.SGD","SG9999013999.USD","LU1868837300.USD","LU1291159041.SGD"],"gpt_icon":0},{"id":"2488160892","title":"礼来(LLY.US)击败诺和诺德(NVO.US) 对比试验中Zepbound优于Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488160892","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488160892?lang=zh_cn&edition=full","pubTime":"2024-12-04 20:28","pubTimestamp":1733315326,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来公司表示，其减肥药Zepbound在首次头对头试验中表现优于竞争对手诺和诺德的Wegovy。在礼来赞助的一项研究中，接受Zepbound治疗的人在72周内平均减掉了体重的20%，约50磅，而接受Wegovy治疗的人只减掉了14%。该结果证实了之前试验所显示的表明Zepbound具有更强效果的结论。该试验包括美国和波多黎各的接受Zepbound或Wegovy最高剂量的751名参与者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e266721f8746851af3f56ae2b1743ae8","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2491050071.SGD","IE0002141913.USD","SG9999014906.USD","LU0417517546.SGD","LU0198837287.USD","SG9999014898.SGD","LU0006306889.USD","SG9999013999.USD","BK4516","LU2237443978.SGD","LU1983299246.USD","IE00B4R5TH58.HKD","LU1291159041.SGD","BK4533","LU2461242641.AUD","IE00BK4W5M84.HKD","SG9999015952.SGD","SGXZ51526630.SGD","LU0061475181.USD","SGXZ31699556.SGD","LU1093756325.SGD","SG9999015945.SGD","LU1061106388.HKD","NVO","IE0004445239.USD","IE00BJLML261.HKD","LU1093756168.USD","SG9999015978.USD","LU2237438978.USD","LU2211815571.USD","LU0203201768.USD","IE00BK4W5L77.USD","LU1868836914.USD","SG9999018857.SGD","LU2361045086.USD","LU0456855351.SGD","GB00BDT5M118.USD","IE0009355771.USD","IE00B2B36J28.USD","LU2360106947.USD","LU2264538146.SGD","LLY","LU2361044949.HKD","LU0672654240.SGD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU1868836591.USD","LU0122379950.USD","LU0203202063.USD","LU2237443622.USD"],"gpt_icon":1},{"id":"2488916283","title":"BUZZ-减肥药在试验中优于竞争对手韦格威，礼来获益匪浅","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916283","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488916283?lang=zh_cn&edition=full","pubTime":"2024-12-04 19:59","pubTimestamp":1733313599,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    12月4日 - ** 美国制药商礼来  的股价在收盘前上涨2%至829.84美元 ** 礼来称其 减肥药Zepbound帮助患者平均减重20.2%，而诺和诺德  的Wegovy减重13.7     ** 在美国上市的诺和诺德  股价下跌约1%，报收于108.56美元。 盘前 ** LLY称Zepbound在  试验 的所有 五个关键次要目标上都 优于Wegovy ** 公司将继续评估试验结果，并计划在明年的医学会议上公布这些结果** 截至上次收盘，LLY上涨了39.5%，诺和诺德在美国上市的股票今年上涨了7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","SG9999017495.SGD","BK4599","LU2361044949.HKD","LU0079474960.USD","BK4585","LU1064131342.USD","LU1267930730.SGD","IE00BFTCPJ56.SGD","LU1868836757.USD","LU2264538146.SGD","LU0689472784.USD","NVO","LU2089984988.USD","LU2491049909.HKD","SG9999015952.SGD","IE00BKVL7J92.USD","IE00B2B36J28.USD","LU0006306889.USD","LU2237438978.USD","IE00BK4W5L77.USD","LU0354030438.USD","LU2468319806.SGD","LU1551013342.USD","LU0094547139.USD","SG9999014898.SGD","LU0471298694.HKD","LU1035775433.USD","LU1917777945.USD","LU1291159041.SGD","BK4581","LU0154236417.USD","LU0114720955.EUR","SGXZ31699556.SGD","LU0289739699.SGD","LU2237443465.HKD","LU0466842654.USD","LU2265009873.SGD","LU0198837287.USD","LU2063271972.USD","SG9999013999.USD","LU0058720904.USD","SG9999018865.SGD","LU1057294990.SGD","LU2491050154.USD","LU1988902786.USD","LLY","LU0456855351.SGD","SG9999001176.USD","LU0354030511.USD"],"gpt_icon":0},{"id":"2488645241","title":"礼来减肥药Zepbound在首次对比试验中超越诺和诺德的Wegovy。当前礼来(LLY.N)美股盘前涨约1.4%，诺和诺德(NVO.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488645241","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488645241?lang=zh_cn&edition=full","pubTime":"2024-12-04 19:51","pubTimestamp":1733313081,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0097036916.USD","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","LU0823416689.USD","LU2265009873.SGD","LU1974910355.USD","LU2063271972.USD","LU1988902786.USD","BK4516","SG9999018857.SGD","LU1035775433.USD","LU1814569148.SGD","LU0114720955.EUR","LU2237443622.USD","BK4599","LU2324357040.USD","LU2461242641.AUD","SG9999001176.USD","SG9999014880.SGD","IE00BK4W5M84.HKD","LLY","LU0154236417.USD","LU0820561818.USD","BK4007","NVO","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU1093756168.USD","LU1868836757.USD","LU0094547139.USD","LU1868837136.USD","LU2491049909.HKD","LU0456855351.SGD","IE00BJJMRZ35.SGD","SG9999015978.USD","SGXZ99366536.SGD","SG9999017495.SGD","LU1280957306.USD","BK4533","LU0417517546.SGD","LU0256863811.USD","LU2237443895.HKD","SG9999015986.USD","LU0354030438.USD","LU0203202063.USD","LU1061106388.HKD","IE00BK4W5L77.USD","LU0466842654.USD","GB00BDT5M118.USD","LU0471298694.HKD"],"gpt_icon":0},{"id":"2488159991","title":"全球减肥大战开打，中国企业重兵出击","url":"https://stock-news.laohu8.com/highlight/detail?id=2488159991","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488159991?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:23","pubTimestamp":1733300586,"startTime":"0","endTime":"0","summary":"说唱歌手胖乔毫不掩饰对让他减了150磅的司美格鲁肽的热爱，埃隆·马斯克则在X.com上大方承认，瘦身的幕后是禁食和Wegory……众人皆知的药品很多，但减肥类药物走向世界，还是第一次。在全球范围内，这样的成年人大概接近9亿，其中在美国和欧洲分别有多达40%和25%的成年人属于肥胖症。美国健康消费公司Hims&Hers Health还在今年5月份宣布，首次推出复合GLP-1减肥注射剂Compound","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/246168","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0154236417.USD","BK4599","NVO","BMI","LU1093756325.SGD","BK4007","BK4585","BK4532","IE00BKVL7J92.USD","LU1093756168.USD","BK4588","BK4157","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2488909727","title":"长春高新“生死竞速”","url":"https://stock-news.laohu8.com/highlight/detail?id=2488909727","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488909727?lang=zh_cn&edition=full","pubTime":"2024-12-04 07:30","pubTimestamp":1733268616,"startTime":"0","endTime":"0","summary":"长春高新的三季报，几乎刷新了近二十年来业绩的新低。2024年前三季度中，长春高新共实现营收103.88亿元，同比下降2.75%；实现归母净利润27.89亿元，同比下降22.8%。长春高新之所以成为国内生长激素龙头，核心原因在于入局时间够早。2023年，长春高新生长激素相关剂型中标浙江省公立医疗机构第四批药品集中带量采购。可见长春高新寻找第二曲线的决心之大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8f0nBkvCGQL","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["BK4599","BK4585","IE00BZ1G4Q59.USD","NVO","LU1093756168.USD","BK4532","BK4588","BK4007","LU0154236417.USD","LU1093756325.SGD","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2488915791","title":"诺和诺德(NVO)盘前涨逾2% 印度团队敦促尽早推出Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488915791","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488915791?lang=zh_cn&edition=full","pubTime":"2024-12-03 19:56","pubTimestamp":1733226981,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)盘前涨逾2%，截至发稿，报110.76美元。消息面上，由于担心在印度这一潜力巨大的市场上落后于竞争对手礼来，丹麦制药巨头诺和诺德的印度团队一直在推动该公司在印度更早推出其广受欢迎的减肥药Wegovy。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"08f768b06424a08465803ba6c2eecb42","isJumpTheme":false,"source_url":"282678","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4599","NVO","LU1093756168.USD","BK4585","BK4007","BK4532","LU0154236417.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2488919660","title":"担心落后于礼来 诺和诺德印度团队据悉敦促提前推出Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488919660","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488919660?lang=zh_cn&edition=full","pubTime":"2024-12-03 19:50","pubTimestamp":1733226652,"startTime":"0","endTime":"0","summary":"诺和诺德高层此前表示，一旦获得监管部门的批准，并且供应充足，Wegovy可能会在2026年进入印度。然而，诺和诺德印度团队最近提议将上市时间提前至2025年，与礼来推出其减重药物Mounjaro的预期时间大致相同。消息人士透露，大约两个月前，在诺和诺德丹麦总部举行的一次闭门会议上，印度团队表达了担忧，称如果Wegovy不能尽早在印度推出，公司可能会在这一市场落后于礼来。据悉，诺和诺德已于2022年底获得印度监管机构对其注射用司美格鲁肽的批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203201510abf2b254&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"08f768b06424a08465803ba6c2eecb42","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203201510abf2b254&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2491049909.HKD","LU2237443622.USD","LLY","LU0708995401.HKD","LU0820561818.USD","LU2237443978.SGD","LU0106261372.USD","IE00BK4W5L77.USD","LU1983299246.USD","LU2237443549.SGD","IE00B1BXHZ80.USD","BK4585","SG9999014906.USD","LU0882574139.USD","LU0385154629.USD","LU2211815571.USD","LU0203201768.USD","IE00BFTCPJ56.SGD","LU0354030438.USD","LU0109391861.USD","LU2324357040.USD","LU2265009873.SGD","IE00BJLML261.HKD","LU1804176565.USD","LU1551013425.SGD","SG9999013999.USD","SGXZ81514606.USD","LU1023059063.AUD","LU2237438978.USD","LU2461242641.AUD","LU2491050154.USD","LU0114720955.EUR","LU0122379950.USD","LU0672654240.SGD","LU0096364046.USD","LU0061475181.USD","LU2237443895.HKD","SG9999014914.USD","SGXZ51526630.SGD","LU0256863811.USD","LU1057294990.SGD","NVO","LU1814569148.SGD","LU1093756325.SGD","LU0354030511.USD","LU0417517546.SGD","LU1267930730.SGD","LU1064131342.USD","IE0004445239.USD","LU0154236417.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0372},{"period":"1month","weight":0.0513},{"period":"3month","weight":-0.1553},{"period":"6month","weight":-0.2247},{"period":"1year","weight":0.1442},{"period":"ytd","weight":0.0708}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0284},{"period":"3month","weight":0.1248},{"period":"6month","weight":0.1382},{"period":"1year","weight":0.3264},{"period":"ytd","weight":0.2788}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S于1989年成立，由两家丹麦公司，诺德根措夫特A/S和Novo工业A/S的合并而成。诺和诺德是一家全球性医疗保健公司，糖尿病治疗的全球领先者。公司拥有业界最广泛的糖尿病产品组合，其中包括新一代胰岛素，现代的完整产品组合，以及作为一个人每日一次的GLP-1类似物之一。此外，诺和诺德在血友病关怀，生长激素疗法和激素替代疗法中也处于领先地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.534884,"avgChangeRate":0.122207},{"month":2,"riseRate":0.604651,"avgChangeRate":0.027007},{"month":3,"riseRate":0.465116,"avgChangeRate":0.01259},{"month":4,"riseRate":0.627907,"avgChangeRate":0.016402},{"month":5,"riseRate":0.545455,"avgChangeRate":0.017073},{"month":6,"riseRate":0.704545,"avgChangeRate":0.027554},{"month":7,"riseRate":0.5,"avgChangeRate":0.005498},{"month":8,"riseRate":0.522727,"avgChangeRate":0.001751},{"month":9,"riseRate":0.568182,"avgChangeRate":-0.002657},{"month":10,"riseRate":0.5,"avgChangeRate":-0.002241},{"month":11,"riseRate":0.613636,"avgChangeRate":0.027229},{"month":12,"riseRate":0.75,"avgChangeRate":0.054427}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}